Modus Therapeutics to present at the annual European Hematology Association Congress, new data on sevuparin and its potential to treat anemia of chronic disease by suppression of hepcidin
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
STOCKHOLM, SWEDEN – May 12, 2023: Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet medical needs, announces that new data on its proprietary clinical candidate drug sevuparin’s ability to potently suppress the iron regulating hormone hepcidin will be presented at the annual meeting of the European Hematology Association (EHA), on June 8-11 in Frankfurt am Main, Germany. Hepcidin plays a key role in controlling the body’s access to iron for vital physiological processes such as the formation of hemoglobin and red blood cells.
The abstract, titled “The non-anticoagulant heparinoid compound, sevuparin, strongly reduces hepcidin expression in cells, in mice and in healthy volunteers” will be presented orally by Dr Michaela Asperti, co-author and a senior member of Professor Maura Poli’s research group at the University of Brescia. The presentation includes preclinical, clinical, and mechanistic data describing the potential of sevuparin to inhibit hepcidin, which is considered the master regulator of iron within the body.
Professor Poli and her team at the University of Brescia have established world-leading research on hepcidin and its role in anemia, a condition in which the number of red blood cells, or the hemoglobin concentration within them is lower than normal. The data to be presented at EHA shows that sevuparin has a broad ability to suppress hepcidin at clinically safe dose levels, which means it could offer a new treatment modality for hepcidin-related disorders such as anemia in chronic kidney disease and other chronic inflammatory disorders.
High levels of hepcidin have been implicated in causing and aggravating the anemias that often complicate chronic kidney disease and chronic inflammation disorders. High hepcidin is also believed to be responsible for conferring resistance to the current standard of care therapies to anemia in non-responding patients.
John Ohd, Chief Executive Officer of Modus Therapeutics commented: “We are fortunate and grateful to have a long-standing collaboration with Professor Poli and her team and the present findings represent a major advance in Modus’ mission to help patients with high unmet medical needs. This work expands the potential use of sevuparin into new and significant therapy areas where Modus is strengthening its IP portfolio. We will continue exploring the broad clinical potential for sevuparin as a treatment in these types of anemia, while at the same time moving forward with its clinical development for sepsis as planned. We look forward to providing further scientific updates on sevuparin at future medical conferences.”
The abstract can be found here: https://library.ehaweb.org/eha/2023/eha2023-congress/387983